Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer

Inclusion criteria

• Patients must have a histologically confirmed diagnosis of cervical cancer
• Diagnostic/pre-treatment biopsy available
• Patients must be suitable for standard radiotherapy and brachytherapy
• Age greater than or equal to 18 years; no upper age limit
• Performance status - ECOG 0-2 (Refer to appendix 1)
• Women of childbearing age MUST have a negative pregnancy test prior to study entry and be using an adequate contraception method
• Before participant registration, written informed consent must be given according to GCP and national regulations.

Exclusion criteria

• Participants deemed unsuitable for a biopsy (during or following radiotherapy) in the opinion of the treating oncologist.
• Patients with cardiac pacemakers, cochlear implants, intraocular foreign bodies or any other MR contraindication
• Patients with a hip replacement
• Patients with a known history of allergic reaction to gadolinium-based contrast agent
• Any contraindications to Hyoscine Butylbromide (Buscopan)
• Any patient taking ACE inhibitors. These should be stopped/substituted or they are a contraindication.
• Evidence of impaired renal function (eGFR <15 ml/min)
• Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the study
• Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the study
• Any other serious uncontrolled medical conditions
• Clinical evidence of metastatic disease
• Any pregnant or lactating woman
• Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
• Any patient who is currently involved in, or who has recently been involved in other research